Viking Therapeutics’ fatty liver drug cuts cholesterol in phase 2 | Digital…
Viking Therapeutics’ lead lipid disorder asset met its primary and secondary endpoints in a midstage trial, dropping cholesterol and liver fat levels in…
Browsing Tag
Phase
VistaGen nabs phase 3-ready social anxiety drug from Pherin | Digital…
VistaGen Therapeutics has licensed Pherin Pharmaceuticals’ lead candidate, a phase 3-ready treatment for social anxiety disorder (SAD). Under the deal,…
Overwatch enters the ‘Humble’ phase of its life | Gaming News
The perfect source for gaming uptodate news
Overwatch is one of the games that Humble Monthly subscribers are getting over the next 30 days as part of that…
EyeGate’s anti-inflammatory eye drug and electric delivery device fail…
EyeGate Pharmaceuticals’ corticosteroid treatment for noninfectious anterior uveitis—delivered directly into the ocular tissue via the company’s device and a…
Another setback for AstraZeneca as lupus drug fails phase 3 test | Digital…
Despite encouraging midstage data for AstraZeneca’s drug for systemic lupus erythematosus (SLE), anifrolumab has missed the target in the first of two ongoing…
Pfizer drops muscle-growth antibody after it misses phase 2 endpoint in DMD…
Pfizer halted two ongoing phase 2 trials of its Duchenne muscular dystrophy drug domagrozumab after the main efficacy study failed to meet its primary endpoint…
Sophiris eyes phase 3 after clearing patient death from its lead study |…
Sophiris Bio has completed its investigation into the death of a patient that halted additional dosing in a trial of its lead candidate topsalysin two months…
Xenon’s epilepsy drug clears phase 1b, setting stage for trial in patients…
A phase 1b trial has linked Xenon’s epilepsy candidate XEN1101 to statistically significant declines in measures of corticospinal and cortical excitability.…
Esperion’s cholesterol drug cuts LDL-C in phase 3 | Digital Science
A phase 3 trial has found that adding Esperion’s bempedoic acid to Zetia lowers LDL cholesterol by more than the statin alone. The result sets Esperion to file…
Zai Lab cans ex-GlaxoSmithKline eczema drug after phase 2 flop | Digital…
Zai Lab has stopped development of a treatment for atopic dermatitis after it failed to beat placebo in a phase 2a trial. The Shanghai-based biotech licensed…